Oliceridine shows potential to reduce PONV in thyroid surgery compared to sufentanil
A study comparing oliceridine to sufentanil in thyroid surgery suggests oliceridine may reduce postoperative nausea and vomiting.
Asset / Drug
Drug and asset intelligence for Oliceridine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.